Cerea Partners, the investor-partner of the food & beverage universe companies, has entered into exclusive negotiations with a view to acquire a majority stake of Polaris alongside the Company’s management and current shareholders who are reinvesting significantly in the transaction (Seventure Partners with its institutional health and food focused strategies, and Picama) as well as French regional investors.

Since its inception in 1994, Polaris has become a major and recognized player in the field of the purification and concentration of oils based on microalgae and fish, making it possible to obtain products with a high concentration of Omega 3. The French Company has a turnover of €30 million and serves the food supplements, nutraceutical and infant nutrition markets, mainly abroad.

Polaris has created a solid reputation thanks to the development of its patented processes aimed at stabilizing and deodorizing the oils, thus improving their longevity, nutritional quality and organoleptic profile.

Seventure Partners first invested in 2009 in Polaris, then became a majority investor in 2021. This has enabled Polaris to move from a distributor to a manufacturer model, and to start industrial production in 2013. In 2018, the Company’s leadership transition was completed with the recruitment of Dominique Taret, as CEO, and Louis Marie Martin, as COO, accelerating organic growth and the development of microbiome-modulating products.

With the support of Cerea Partners, as the new majority shareholder, Polaris is entering a new phase of its development, which revolves around three main areas:
  • The strengthening of its know-how in microalgae oils;
  • The pursuit of international development, particularly in North America and Asia;
  • The development of new applications (particularly in infant nutrition and food) which could be accompanied by targeted external growth.
Dominique Taret, CEO of Polaris, said:

“Cerea and Seventure share the same vision and strategy for Polaris. This unity of investors’ thinking for Polaris is extremely important for the Company’s ambition to consolidate its leadership on the Omega 3 microalgae bases processes market.”

Isabelle de Crémoux, CEO and managing partner of Seventure Partners, said:

“Polaris has all the ingredients for success: premium products recognized by hundreds of customers which allow us to preserve health capital, take advantage of a wide range of applications of the microbiota while having a positive environmental impact, as well as a new management team that has demonstrated it can deliver its vision. As a player committed to the planet and health, this investment was obvious for our health and food focused strategies and that is why we will be significantly reinvesting in this primary LBO. We are delighted to combine impact and high financial performance.”
Seventure Partners, a portfolio management company, is a subsidiary of Natixis Investment Managers, authorized by the AMF (Autorité des Marchés Financiers) under number GP 01-040.

Seventure Partners, a privately owned French company with a Management Board and a Supervisory Board with a capital of €362,624.
Registered office: 5/7, rue de Monttessuy, 75007 Paris – 327 205 258 RCS Paris

Natixis Investment Managers
RCS Paris 453 952 681
Share Capital: €178 251 690
43 avenue Pierre Mendès France
75013 Paris

This communication is for information only and is intended for investment service providers or other Professional Clients. The analyses and opinions referenced herein represent the subjective views of the author as referenced unless stated otherwise and are subject to change. There can be no assurance that developments will transpire as may be forecasted in this material.